Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2005 Nov;6(14):2525-34.

Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease.

Author information

  • 1Unità Operativa di Malattie dell'Apparato Respiratorio, Ospedale San Paolo, Università degli Studi di Milano, Via A. di Rudinì 8, 20142, Milan, Italy. stefano.centanni@unimi.it

Erratum in

  • Expert Opin Pharmacother. 2005 Dec;6(15):2779.

Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality throughout the world. Current guidelines recommend the addition of inhaled steroids to bronchodilators, which are central to the symptomatic management of COPD in patients with severe disease. Budesonide/formoterol is a combination inhaled steroid and long-acting bronchodilator delivered by a dry-powder inhaler, approved for use in COPD. Two large, randomised, double-blind, 12-month studies found that combination budesonide/formoterol is more effective than either component alone in addressing many important aspects of the disease, such as pulmonary function, symptoms, use of relief medication, health-related quality of life and exacerbation in patients suffering from severe COPD. This review discusses the pharmacological and clinical properties of the drug.

PMID:
16259583
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk